RRM2 and small cell lung carcinoma: (Fig 9E) Methotrexate, Oxaliplatin, Sunitinib, Bicalutamide, Afureserti, Azathioprine, Dasatinib, Hydroxyurea and Topotecan might be viewed as targeted drugs for the treatment of SCLC patients with high expression of RRM2.